However, the histopathological features, clinical presentation, presence of a BRAF mutation, and the sustained therapeutic response to targeted therapy collectively support the diagnosis of a low‐grade glioma, most consistent with pleomorphic xanthoastrocytoma. This evidence concerns the gene BRAF and central nervous system cancer.